More Than 90 Vision Claims Follow the GLP-1 Boom

More than 90 lawsuits filed in New Jersey state court since 2025 allege that Novo Nordisk’s GLP-1 medicines caused nonarteritic anterior ischemic optic neuropathy, or NAION, a rare interruption of blood flow that damages the optic nerve and can leave permanent vision loss. The reporting names Novo’s Ozempic and Wegovy among the market’s prominent drugs and also discusses Eli Lilly products Mounjaro and Zepbound. Novo says the cases lack merit and is contesting them; Lilly says it is reviewing data on possible health risks. Allegations are not findings of causation.

One Pennsylvania plaintiff described her vision after diabetes treatment as resembling a view through a fishbowl and said she received a NAION diagnosis two weeks later. That sequence is important to her claim, but sequence alone cannot prove cause. The scientific evidence remains mixed, and the reporting says researchers have observed cases within roughly six to 18 months after patients started GLP-1 medication. The supplied account does not establish the warning language each plaintiff received or what each prescriber knew at the time.

The risk outside the transformation frame

GLP-1 medicines have acquired a social life larger than the prescription pad. They appear through shrinking waistlines, scarce appointments, high prices, celebrity disclosure, and the polished grammar of reinvention. The smaller body dominates the advertisement. The eye must still be monitored. A rare danger can disappear inside that spectacle because it does not photograph as neatly as weight lost or clothing newly fitted.

That does not make the drugs a fraud. They can provide meaningful treatment for diabetes and obesity, and frightened patients may be harmed if they abandon prescribed medicine without medical advice. The responsible comparison is numerical: NAION incidence among similar untreated patients, incidence among users of each drug, timing after initiation, dose and duration, trial findings, adverse-event reports, and the influence of the underlying illnesses for which these medicines are prescribed.

Informed consent should not require certainty that science has not reached. Prescribers can explain that a possible association is under study, that NAION is rare and often irreversible, and that the patient’s own benefits and risks deserve review. Manufacturers, meanwhile, should publish usable absolute numbers rather than allowing legal denials or lifestyle branding to stand in for evidence. Prestige does not reduce risk; it merely improves the lighting.

Anyone experiencing sudden, painless loss or major distortion of vision should seek urgent medical and eye care rather than waiting for a routine appointment, while medication changes should be discussed with the treating clinician. The lawsuits will test what companies disclosed, but better studies must determine whether the drugs change risk beyond the conditions already common among their users. Patients need that distinction before either the courtroom or the campaign image makes the decision for them.